Company intelligence / Profile preview

FinVector

Ownership: Private
Employees: ~500
Development stage: Other

Overview

FinVector manufactures Adstiladrin®—an adenoviral vector-based gene therapy—for non-muscle invasive bladder cancer. The drug received FDA approval in December 2022. The company operates one of the world’s largest viral vector manufacturing facilities and serves as a global center of excellence within Ferring Group. Its focus has shifted from R&D to commercial production following regulatory success.

Therapeutic areas: Oncology
Modalities: Gene therapyViral vector-based gene therapyBiologic
Industry: Biotech

Partnerships

Close collaboration with University of Eastern Finlandpart of the broader Ferring Group ecosystem

Beyond the preview

Go deeper on FinVector.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FinVector.

Explore the full profile